JEOL: New CROSS SECTION POLISHER™ IB-19540CP / IB-19550CCP Released
4.9.2024 05:00:00 EEST | Business Wire | Press release
JEOL Ltd. (TOKYO:6951)(President and CEO: Izumi Oi) announces the release of the New CROSS SECTION POLISHER™ IB-19540CP / COOLING CROSS SECTION POLISHER™ IB-19550CCP for Electron Microscopes on September 4, 2024.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20240903942772/en/
CROSS SECTION POLISHER™ IB-19540CP (Photo: Business Wire)
CROSS SECTION POLISHER™（CP）is widely utilized in the fields of electronic parts, ceramics, life science, metal, battery, and polymer. The mechanical high-quality uniform cross section can be easily prepared for complex materials and fragile specimens.
With a sales record of over 2,000 units since its launch in 2003, the CP has been an essential tool for pre-treatment.
The IB-19540CP / IB-19550CCP have been advanced with enhanced user-friendliness. Incorporation of the new GUI and IoT (Internet of Things) further improves ease of use and enables remote control and milling process monitoring by PC. High throughput ion source and high throughput cooling system enable preparation of a smooth cross section rapidly with less damages.
Main features
1. New GUI and Internet of Things (IoT)
Incorporation of a new GUI makes the operation steps easy to understand.
Easy setup is possible by following the flowchart on the control panel.
Preset functions are available for saving and recalling process conditions tailored to specific applications or specimen types.
Connecting to LAN provides remote access and control through a web browser to the CP.
Monitoring and adjusting the milling process over multiple CPs is possible.
2. High throughput ion source
High throughput ion source is equipped as a standard. The ion current density has been improved by optimizing the ion-source electrode and increasing the accelerating voltage. The standard cross section milling rate is now 1,200 μm/h* and it will help reduce the time required for processing.
*Milling of 1 h, Si equivalent, Edge distance: 100 μm
3. High throughput cooling system
The high throughput cooling system and the new GUI enable automatic operation from cooling to return to room temperature. Thus, the waiting time has been reduced and it helps shorten the time required for work.
It is possible to vacuum around the liquid nitrogen tank from the CP side to maintain cooling retention time and specimen cooling temperature.
Annual Unit Sales Target
180 units/year
Related link
Product Information : CROSS SECTION POLISHER™ IB-19540CP / COOLING CROSS SECTION POLISHER™ IB-19550CCP
https://www.jeol.com/products/scientific/cp/IB-19540CP_IB-19550CCP.php
JEOL Ltd.
3-1-2, Musashino, Akishima, Tokyo, 196-8558, Japan
Izumi Oi, President & CEO
(Stock code: 6951, Tokyo Stock Exchange Prime Market)
www.jeol.com
View source version on businesswire.com: https://www.businesswire.com/news/home/20240903942772/en/
Contacts
JEOL Ltd.
Science and Measurement Instruments Sales Division
TEL: +81-3-6262-3567
https://www.jeol.com/contacts/products.php -
https://cts.businesswire.com/ct/CT?id=smartlink&url=https%3A%2F%2Fwww.jeol.com%2
Fcontacts%2Fproducts.php&esheet=54113890&newsitemid=20240903942772&lan=en-US&anc
hor=https%3A%2F%2Fwww.jeol.com%2Fcontacts%2Fproducts.php&index=3&md5=c7b0e65d496
5b076efb40a1540e7569b
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
www.businesswire.com
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Techtronic Industries Delivers Strong First Half Performance4.8.2026 14:20:00 EEST | Press release
Techtronic Industries Co. Ltd. (“TTI” or the “Group”) (stock code: HK: 0669, ADR symbol: TTNDY), a global cordless power tool, outdoor power equipment and floorcare & cleaning company, is pleased to announce its results for the six-month period ended June 30, 2026. The Group delivered record first half results in 2026, with revenue growing 5.9% to US$8.3 billion. Its two leading brands, MILWAUKEE and RYOBI, both delivered a strong performance in the first half of 2026, growing at a combined 8.2% underlying growth rate in local currency. TTI delivered record first half results in 2026, with revenue growing 5.9% to US$8.3 billion and net profit increasing 17.5% to US$738 million. Our global MILWAUKEE business grew 10.5% on an underlying basis in local currency, after adjusting for the planned 2025 timing impact related to the MILWAUKEE Americas ERP system conversion. RYOBI, the #1 global consumer cordless tool and outdoor products brand, grew 1.7% in local currency to US$1.9 billion in t
WHOOP Expands Commitment to Women's Health by Including One-Year Subscription of Natural Cycles° App in Membership4.8.2026 12:00:00 EEST | Press release
WHOOP, the human performance company, today announced an expansion of its women’s health offering through an integration with Natural Cycles° (NC°), the only FDA-cleared, hormone-free birth control app. WHOOP is offering a 12-month subscription to the NC° app to eligible new Natural Cycles users. Members with compatible WHOOP devices can now automatically share overnight skin temperature with the NC° app to enable personalized fertility insights and hormone-free birth control. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260804399367/en/ WHOOP Expands Commitment to Women's Health by Including One-Year Subscription of Natural Cycles° App in Membership The Natural Cycles app, a Class II medical device, uses biomarker data, including temperature and heart rate data, to identify fertile and non-fertile days, helping users prevent pregnancy without hormones while also providing fertility insights. Beyond birth control, the app
Alphatax Makes Two Acquisitions to Strengthen Transfer Pricing Capabilities4.8.2026 11:00:00 EEST | Press release
Alphatax, the global tax compliance software provider, has today announced the acquisitions of TP Accurate and Intra Pricing Solutions, expanding its transfer pricing capabilities and reinforcing its ambition to build the world's first tax operating system. The acquisitions strengthen Alphatax's transfer pricing portfolio with complementary capabilities across financial transactions and documentation. TP Accurate provides specialist software for intra-group financing arrangements, while Intra Pricing Solutions' flagship product, TPGenie, enables multinational organisations and advisors to produce transfer pricing documentation using intelligent automation and AI. Together, they expand Alphatax's ability to support the full transfer pricing lifecycle, helping customers manage compliance more efficiently while improving governance and reducing audit risk. They also represent another step towards Alphatax's long-term vision for the future of tax technology. By bringing these transfer pric
LabPMM® Launches Global KMT2A MRD Testing Service to Support Menin Inhibitor Development and Acute Leukemia Care4.8.2026 10:10:00 EEST | Press release
LabPMM®, an Invivoscribe® subsidiary, today announced the global availability of its new KMT2A measurable residual disease (MRD) testing service. The highly sensitive digital PCR service is available to healthcare providers, clinical researchers, and biopharmaceutical partners through LabPMM’s global laboratory network, with CAP/CLIA-accredited testing available in the U.S. The service addresses a growing need for accurate molecular monitoring in acute leukemias.1,2,3 KMT2A rearrangements (KMT2Ar) are oncogenic drivers in acute myeloid leukemia (AML) and acute lymphoblastic leukemia (ALL).4 These rearrangements are present in about 80% of infant cases and 5-15% of childhood and adult leukemia cases.5 KMT2Ar leukemias are associated with chemotherapy resistance, high relapse rates, and poor clinical outcomes.5 The emergence of menin inhibitors is transforming the therapeutic landscape for patients with AML and ALL, particularly those with KMT2A-rearranged and NPM1-mutated disease.6 The
Mosaic Therapeutics appoints Dr Allison Jeynes as Chair of the Board4.8.2026 10:00:00 EEST | Press release
Mosaic Therapeutics, Ltd, (‘Mosaic’, or ‘the Company’) an oncology therapeutics company developing novel, targeted drug combinations across a range of haematological and solid cancers, today announced the appointment of Dr Allison Jeynes as Chair of the Board to support its next phase of growth and advancement towards clinical development. Allison succeeds Dr Edward Hodgkin, who remains a Non-Executive Director of the Board. Allison is a UK-trained oncologist and highly-experienced life sciences leader, and brings over three decades of drug development and executive experience to Mosaic Therapeutics. As CEO of Avillion, a clinical development company, for the last 13 years, she has led global teams to achieve a 100% success rate from Phase 3 development through to FDA approval for multiple programs spanning oncology, immunology and respiratory medicine. In addition, she raised funds of around $400M as founder and CEO. Across her career she has contributed to 20 drug approvals, engaging
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom